Immunocore Holdings Company Description

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases.

The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma.

It also develops other programs for oncology, including tebentafusp that is in Phase 3 clinical trial to treat advanced cutaneous melanoma and adjuvant uveal melanoma; and brenetafusp that is in Phase 3 clinical trial to treat first-line advanced cutaneous melanoma and in a Phase 1/2 clinical trial in multiple tumor types.

In addition, the company’s products under development include IMC-R117C (PIWIL-1) that is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, including colorectal cancer; IMC-P115C (PRAME-HLE-A02) that is in Phase 1 clinical trial for patients with tumors that express PRAME; IMC-M113V that is in Phase 1 clinical trials for a potential functional cure in human immunodeficiency virus (HIV); and IMC-I109V that is in Phase 1 clinical trials for a potential functional cure in hepatitis B virus (HBV).

Further, it develops IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-S118AI to treat type 1 diabetes; and IMC-U120AI to treat atopic dermatitis.

Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

Immunocore Holdings plc

Country	United Kingdom
Founded	1999
Industry	Biological Products, Except Diagnostic Substances
Employees	493
CEO	Bahija Jallal

Contact Details

Address: 92 Park Drive Abingdon, OX14 4RY United Kingdom
Phone	44 12 3543 8600
Website	immunocore.com

Stock Details

Ticker Symbol	6YG
Exchange	Frankfurt Stock Exchange
Fiscal Year	January - December
Reporting Currency	USD
SIC Code	2836

Key Executives

Name	Position
Bahija Jallal	Chief Executive Officer
Travis Coy	Chief Financial Officer
John Trainer	Chief Operating Officer
Clayton Robertson	Head of Investor Relations